QNRX furnishes Item 2.02 press release on Q3 2025 results

Rhea-AI Filing Summary

Quoin Pharmaceuticals Ltd. furnished a Form 8-K announcing its third quarter financial results. The announcement was made on November 6, 2025, with a detailed press release attached as Exhibit 99.1.

The company stated that the information provided under Item 2.02 is not deemed “filed” for purposes of Section 18 of the Exchange Act and is incorporated by reference only as specified. Quoin’s American Depositary Shares trade on Nasdaq under the symbol QNRX, with each ADS representing thirty-five ordinary shares.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001671502 0001671502 2025-11-06 2025-11-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 6, 2025

QUOIN PHARMACEUTICALS LTD.

(Translation of registrant’s name into English)

State of Israel		001-37846		92-2593104
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

42127 Pleasant Forest Court Ashburn, VA		20148-7349
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (703) 980-4182

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
American Depositary Shares, each representing Thirty-five (35) Ordinary Shares, no par value per share		QNRX		The Nasdaq Stock Market LLC
Ordinary Shares, no par value per share*				N/A

* Not for trading, but only in connection with the registration of the American Depositary Shares pursuant to requirements of the Securities and Exchange Commission.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02 Results of Operations and Financial Condition.

On November 6, 2025 Quoin Pharmaceuticals Ltd. (the “Company”) announced its third quarter financial results. A copy of the Company’s press release is attached as Exhibit 99.1 hereto and incorporated by reference herein.

The information set forth and incorporated by reference in this Item 2.02 shall not be deemed to be “filed” with the Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and the Company does not incorporate it by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release, dated November 6, 2025
104		Cover Page Interactive Data file (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

Date: November 6, 2025	QUOIN PHARMACEUTICALS LTD.
	By:	/s/ Sally Lawlor
	Name:	Sally Lawlor
	Title:	Chief Financial Officer

FAQ

What did QNRX announce in this filing?

Quoin Pharmaceuticals announced its third quarter financial results and furnished a press release as Exhibit 99.1.

What form did QNRX file and when?

The company filed a Form 8-K on November 6, 2025.

Which 8-K item applies to this announcement?

Item 2.02 (Results of Operations and Financial Condition).

Is the press release considered filed or furnished?

It is not deemed “filed” under Section 18 of the Exchange Act; it is furnished and incorporated by reference as indicated.

What exhibit contains the detailed results?

The detailed results are in Exhibit 99.1 (Press Release).

What is QNRX’s trading symbol and listing?

The trading symbol is QNRX, and the ADSs are listed on The Nasdaq Stock Market LLC.

Who signed the report for QNRX?

It was signed by Sally Lawlor, Chief Financial Officer.